Aquestive Therapeutics, Inc. AQST Royalty Obligations, Net
Royalty Obligations, Net at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:RoyaltyObligationsNet.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s royalty obligations, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s royalty obligations, net?
- Aquestive Therapeutics, Inc. (AQST) reported royalty obligations, net of $25.94M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s royalty obligations, net?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s royalty obligations, net has grown at a 32.6% compound annual growth rate (CAGR), from $14.76M to $25.94M.
- What does royalty obligations, net mean?
- This represents the net liability owed to third parties for the use of licensed technology or intellectual property, adjusted for any prepayments or offsets. It reflects the ongoing cost of maintaining access to essential patents or drug delivery platforms. Managing this obligation is crucial for maintaining long-term profitability in a licensing-heavy business model.